IP Library Granted Patent US 12,371,479
Granted Patent B2
US 12,371,479 · App. 17/423,999 · Granted Jul 29, 2025

Anti-elastin antibodies and methods of use

Inventors: Narendra R. Vyavahare (Clemson, SC); Charles D. Rice (Clemson, SC); Nasim Nosoudi (Clemson, SC); Saketh Karamched (Clemson, SC); Vaideesh Parasaram (Clemson, SC)
Assignee: CLEMSON UNIVERSITY RESEARCH FOUNDATION
C07K16/18A61K39/3955A61K47/6843A61K49/0058C07K14/78G01N33/53G01N33/6887A61K2039/505G01N2333/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,479
App. No.
17/423,999
Granted
Jul 29, 2025
Kind
B2
Abstract

Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and/or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and/or imaging agents. Optionally, the antibodies and/or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber.

Claims (20)

1. An antibody or antigen binding fragment thereof which binds to degraded elastin, the antibody or antigen binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 27, SEQ ID NO: 29, and SEQ ID NO: 31.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody is a polyclonal antibody.

4. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is an antibody that is a fully human antibody, a non-human antibody, a chimeric antibody, a humanized antibody, or a single domain antibody.

5. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is an antigen binding fragment that comprises a Fab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, or a scFv.

6. A composition comprising the antibody or antigen binding fragment thereof of claim 1 directly or indirectly operably linked to a secondary material.

7. The composition of claim 6 , wherein the secondary material comprises a biologically active agent.

8. The composition of claim 7 , wherein the biologically active agent comprises an anticoagulant, an antiplatelet, an anti-inflammatory, an SMC proliferation inhibitor, a matrix metalloproteinase inhibitor, a cathepsin inhibitor, a cytostatic agent, an anti-oxidant, a collagen stabilizing agent, an elastin-stabilizing agent, an elastin regeneration agent, a cytokine, an enzyme, a chemokine, a radioisotope, a toxin, an immunomodulatory agent, a chelator, a nucleic acid construct, a chemotherapeutic agent, an elastin crosslinking agent or a tropoelastin crosslinking agent.

9. The composition of claim 6 , wherein the secondary material comprises an imaging agent.

10. The composition of claim 9 , wherein the imaging agent comprises a photoactivatable agent, a fluorophore, a radioisotope, a bioluminescent peptide, a fluorescent tag, a fluorescent peptide, an affinity label, an enzymatic label, an MRI agent, a gold particle, an x-ray opaque substance, or an isotopic label.

11. The composition of claim 6 , wherein the secondary material comprises a carrier.

12. The composition of claim 11 , wherein the carrier comprises a liposome.

13. The composition of claim 11 , wherein the carrier is a particle.

14. The composition of claim 13 , wherein the particle is a nanoparticle.

15. The composition of claim 13 , wherein the particle comprises a degradable polymer.

16. The antibody or antigen binding fragment thereof of claim 1 , comprising the amino acid sequence of SEQ ID NO: 7.

17. The antibody or antigen binding fragment thereof of claim 1 , comprising the amino acid sequence of SEQ ID NO: 25.

18. A method of binding to degraded elastin fiber comprising contacting a degraded elastic fiber with an antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is operably linked to a secondary material.

19. The method of claim 18 , wherein the secondary material comprises a carrier and a biologically active agent incorporated into the carrier, wherein the biologically active agent is released from the carrier following the binding of the antibody or antigen binding fragment thereof to the degraded elastic fiber.

20. The method of claim 18 , the secondary material comprising an imaging agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2023
From: VYAVAHARE, NARENDRA R.; RICE, CHARLES D.; NOSOUDI, NASIM; KARAMCHED, SAKETH; PARASARAM, VAIDEESH
To: CLEMSON UNIVERSITY
Reel/Frame 062942/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2023
From: CLEMSON UNIVERSITY
To: CLEMSON UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 062948/0031 →
Continuity (1)
Related Publication 20220089706A1 · Mar 24, 2022
References Cited (93)
US 3918455A · Coplan · 1975 [cited by applicant]
US 3997396A · Delente · 1976 [cited by applicant]
US 4027676A · Mattei · 1977 [cited by applicant]
US 5123912A · Kaplan et al. · 1992 [cited by applicant]
US 5162225A · Sager et al. · 1992 [cited by applicant]
US 5200248A · Thompson et al. · 1993 [cited by applicant]
US 5242644A · Thompson et al. · 1993 [cited by applicant]
US 5263984A · Li et al. · 1993 [cited by applicant]
US 5268229A · Phillips et al. · 1993 [cited by applicant]
US 5496627A · Bagrodia et al. · 1996 [cited by applicant]
US 5512600A · Mikos et al. · 1996 [cited by applicant]
US 5518680A · Cima et al. · 1996 [cited by applicant]
US 5611981A · Phillips et al. · 1997 [cited by applicant]
US 5716404A · Vacanti et al. · 1998 [cited by applicant]
US 5723159A · Phillips et al. · 1998 [cited by applicant]
US 5759830A · Vacanti et al. · 1998 [cited by applicant]
US 5770193A · Vacanti et al. · 1998 [cited by applicant]
US 5804318A · Pinchuk et al. · 1998 [cited by applicant]
US 5906828A · Cima et al. · 1999 [cited by applicant]
US 5942436A · Dunn et al. · 1999 [cited by applicant]
US 5972505A · Phillips et al. · 1999 [cited by applicant]
US 6303136B1 · Li et al. · 2001 [cited by applicant]
US 6306424B1 · Vyakarnam et al. · 2001 [cited by applicant]
US 6333029B1 · Vyakarnam et al. · 2001 [cited by applicant]
US 6365149B2 · Vyakarnam et al. · 2002 [cited by applicant]
US 6368859B1 · Atala · 2002 [cited by applicant]
US 6391538B1 · Vyavahare et al. · 2002 [cited by applicant]
US 6468649B1 · Zhong · 2002 [cited by applicant]
US 6521431B1 · Kiser et al. · 2003 [cited by applicant]
US 6544548B1 · Siller-Jackson et al. · 2003 [cited by applicant]
US 6753311B2 · Fertala et al. · 2004 [cited by applicant]
US 6790455B2 · Chu et al. · 2004 [cited by applicant]
US 6858222B2 · Nelson et al. · 2005 [cited by applicant]
US 6861142B1 · Wilkie et al. · 2005 [cited by applicant]
US 6861211B2 · Levy et al. · 2005 [cited by applicant]
US 7056580B2 · Dugan · 2006 [cited by applicant]
US 7374673B2 · Marcus · 2008 [cited by applicant]
US 7479164B2 · Girardot et al. · 2009 [cited by applicant]
US 7713543B2 · Vyavahare et al. · 2010 [cited by applicant]
US 7918899B2 · Girardot et al. · 2011 [cited by applicant]
US 8926974B2 · Griswold-Prenner · 2015 [cited by examiner]
US 9795573B2 · Vyavahare et al. · 2017 [cited by applicant]
US 10112990B2 · Adolfsson · 2018 [cited by examiner]
US 10688061B2 · Vyavahare et al. · 2020 [cited by applicant]
US 20010033857A1 · Vyakarnam et al. · 2001 [cited by applicant]
US 20020022883A1 · Burg · 2002 [cited by applicant]
US 20050070930A1 · Kammerer · 2005 [cited by applicant]
US 20090104215A1 · Ekiel et al. · 2009 [cited by applicant]
US 20110129531A1 · Collette et al. · 2011 [cited by applicant]
US 20120045781A1 · Veidal et al. · 2012 [cited by applicant]
US 20140017263A1 · Vyavahare et al. · 2014 [cited by applicant]
US 20140086921A1 · Griswold-Prenner et al. · 2014 [cited by applicant]
US 20140193420A1 · Aburatani et al. · 2014 [cited by applicant]
US 20150087611A1 · Vyavahare et al. · 2015 [cited by applicant]
US 20150344548A1 · Simard · 2015 [cited by applicant]
US 20170002047A1 · Jimenez et al. · 2017 [cited by applicant]
US 20170015742A1 · Gu et al. · 2017 [cited by applicant]
US 20170209592A1 · Vyavahare et al. · 2017 [cited by applicant]
US 20170275376A1 · Igawa et al. · 2017 [cited by applicant]
US 20180036261A1 · Vyavahare et al. · 2018 [cited by applicant]
US 20200276131A1 · Vyavahare et al. · 2020 [cited by applicant]
JP 2011503564 · 2011 [cited by applicant]
WO WO0047716 · 2000 [cited by applicant]
WO WO2006115733 · 2006 [cited by applicant]
WO WO2015104342A1 · 2015 [cited by applicant]
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Comm 307: 198-205, 2003. [cited by examiner]
Chen et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293: 865-881, 1999. [cited by examiner]
De Pascalis et al. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J I… [cited by examiner]
Holm et al. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol 44: 1075-1084, 2007. [cited by examiner]
Lei et al. Targeted chelation therapy with EDTA-loaded albumin nanoparticles regresses arterial calcification without causing systemic side effects. J Controlled Release 196: 79-86, 2014. [cited by examiner]
MacCallum et al. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262: 732-745, 1996. [cited by examiner]
Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles. Pulmon Pharmacol Therpeutics 39: 64-73, 2016. [cited by examiner]
Paul, William E., Fundamental Immunology, 3rd Edition, Raven Press, New York, Chapt. 8, pp. 292-295 (1993). [cited by examiner]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA 79: 1979-1983, 1982. [cited by examiner]
Zhang et al. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1): 42-52, 2015 (published online Nov. 21, 2014). [cited by examiner]
Bunge, M.B. “Bridging Areas of Injury in the Spinal Cord” [cited by applicant]
Conroy, et al. “Lubricious coatings for medical devices” [cited by applicant]
Cruise, et al. “Characterization of permeability and network structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels” [cited by applicant]
Harris, et al. “Assessment of the cytocompatibility of different coated titanium surfaces to fibroblasts and osteoblasts” [cited by applicant]
ISA. “International Search Report and Written Opinion” PCT/US2019/014537 (May 7, 2019) pp. 1-12. [cited by applicant]
Park, J.B. “Biomaterials: An Introduction” [cited by applicant]
Ratner, et al. “Biomaterials Science: An Introduction to Materials in Medicine” [cited by applicant]
Sawhney, et al. “Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromers” [cited by applicant]
Wei, et al. “Epitope specificity of monoclonal and polyclonal antibodies to human elastin” [cited by applicant]
Yeo, et al. “Tropoelastin bridge region positions the cell-interactive C terminus and contributes to elastic fiber assembly” [cited by applicant]
Binder et al. “Half-Life Extension of Therapeutic Proteins via Genetic Fusion to Recombinant PEG Mimetics” Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives pp. 63-80, 2012. [cited by applicant]
Fiedler et al. “Non-Antibody Scaffolds as Alternative Therapeutic Agents” Handbook of Therapeutic Antibodies, Second Edition 2014 pp. 435-474. [cited by applicant]
Urban et al. “Cytochrome P450 (Cyp) mutants and substrate-specificity alterations: segment-directed mutagenesis applied to human CYPIAI” Biochemical Society: Protein Engineering of Peroxidases and Cytochrome P450 2001 p… [cited by applicant]
Barroso et al., “Study of human lung elastin degradation by different elastases using high-performance liquid chromatography/mass spectrometry”, Analytical Biochemistry, vol. 358, 2006, pp. 216-224. [cited by applicant]
Kristensen et al., “Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling”, BMC Pulmonary Medicine, 2015, 7 pages, 15:53. [cited by applicant]
Skjot-Arkil et al., “Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAs”, PLOS One, vol. 8, Issue 6, Jun. 2013, 11 pages, e60936. [cited by applicant]
Supplementary European Search Report, dated Sep. 6, 2022, 3 pages, for EP 19911987. [cited by applicant]
Office Action from JP, Mailed on Mar. 6, 2024, 4 pages. [cited by applicant]